Article info

Download PDFPDF
Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci

Authors

  1. Correspondence to Dr Bente Glintborg, Department of Rheumatology, Gentofte and Herlev University Hospital, Hellerup 3500, Denmark; glintborg{at}dadlnet.dk
View Full Text

Citation

Glintborg B, Loft AG, Omerovic E, et al
Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci

Publication history

  • Received December 4, 2018
  • Accepted December 5, 2018
  • First published December 20, 2018.
Online issue publication 
May 11, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.